Monday , 20 November 2017

Home » RESOURCES » INVESTING » Intercept shares rally on FDA panel vote for liver drug

Intercept shares rally on FDA panel vote for liver drug

Intercept Pharmaceuticals Inc. shares rallied in the extended session Thursday after a Food and Drug Administration advisory committee receommended an accelerated approval of the biotech’s liver treatment Ocaliva. Intercept shares surged 9% to $178.40 after hours. Intercept said the FDA’s Gastrointestinal Drugs Advisory Committee voted 17-0 to approve Ocaliva to treat primary biliary cholangitis, a liver disease that destroys bile ducts and causes cirrhosis. The FDA is not required to follow advisory committee recommendations but does for the most part.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Intercept shares rally on FDA panel vote for liver drug Reviewed by on . Intercept Pharmaceuticals Inc. shares rallied in the extended session Thursday after a Food and Drug Administration advisory committee receommended an accelerat Intercept Pharmaceuticals Inc. shares rallied in the extended session Thursday after a Food and Drug Administration advisory committee receommended an accelerat Rating:
scroll to top